IS BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUG USE IN PATIENTS WITH AUTOIMMUNE DISEASES A RISK FACTOR FOR SEVERE SARS-COV-2 INFECTION?

Detalles Bibliográficos
Autores principales: WAQAR, HAFIZA HAREEM, MAHMOOD, FATIMA, NAUTIYAL, AMIT
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American College of Chest Physicians. Published by Elsevier Inc. 2022
Materias:
Lung Pathology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9548847/
http://dx.doi.org/10.1016/j.chest.2022.08.1547
_version_ 1784805527538106368
author WAQAR, HAFIZA HAREEM
MAHMOOD, FATIMA
NAUTIYAL, AMIT
author_facet WAQAR, HAFIZA HAREEM
MAHMOOD, FATIMA
NAUTIYAL, AMIT
author_sort WAQAR, HAFIZA HAREEM
collection PubMed
description
format Online
Article
Text
id pubmed-9548847
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American College of Chest Physicians. Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-95488472022-10-11 IS BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUG USE IN PATIENTS WITH AUTOIMMUNE DISEASES A RISK FACTOR FOR SEVERE SARS-COV-2 INFECTION? WAQAR, HAFIZA HAREEM MAHMOOD, FATIMA NAUTIYAL, AMIT Chest Lung Pathology American College of Chest Physicians. Published by Elsevier Inc. 2022-10 2022-10-10 /pmc/articles/PMC9548847/ http://dx.doi.org/10.1016/j.chest.2022.08.1547 Text en Copyright © 2022 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Lung Pathology
WAQAR, HAFIZA HAREEM
MAHMOOD, FATIMA
NAUTIYAL, AMIT
IS BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUG USE IN PATIENTS WITH AUTOIMMUNE DISEASES A RISK FACTOR FOR SEVERE SARS-COV-2 INFECTION?
title IS BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUG USE IN PATIENTS WITH AUTOIMMUNE DISEASES A RISK FACTOR FOR SEVERE SARS-COV-2 INFECTION?
title_full IS BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUG USE IN PATIENTS WITH AUTOIMMUNE DISEASES A RISK FACTOR FOR SEVERE SARS-COV-2 INFECTION?
title_fullStr IS BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUG USE IN PATIENTS WITH AUTOIMMUNE DISEASES A RISK FACTOR FOR SEVERE SARS-COV-2 INFECTION?
title_full_unstemmed IS BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUG USE IN PATIENTS WITH AUTOIMMUNE DISEASES A RISK FACTOR FOR SEVERE SARS-COV-2 INFECTION?
title_short IS BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUG USE IN PATIENTS WITH AUTOIMMUNE DISEASES A RISK FACTOR FOR SEVERE SARS-COV-2 INFECTION?
title_sort is biologic disease-modifying antirheumatic drug use in patients with autoimmune diseases a risk factor for severe sars-cov-2 infection?
topic Lung Pathology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9548847/
http://dx.doi.org/10.1016/j.chest.2022.08.1547
work_keys_str_mv AT waqarhafizahareem isbiologicdiseasemodifyingantirheumaticdruguseinpatientswithautoimmunediseasesariskfactorforseveresarscov2infection
AT mahmoodfatima isbiologicdiseasemodifyingantirheumaticdruguseinpatientswithautoimmunediseasesariskfactorforseveresarscov2infection
AT nautiyalamit isbiologicdiseasemodifyingantirheumaticdruguseinpatientswithautoimmunediseasesariskfactorforseveresarscov2infection

Ejemplares similares